Resolution of XXXX after HLA-mismatched unrelated @entity1503 for @entity2590 .

@entity1 @entity154 @entity7139 @entity417 @entity9645 @entity2590 @entity1503 @entity3043 @entity1398 @entity2132 @entity195 @entity221 @entity5406
In 1991, a 27-year-old @entity1 who presented with recurrent @entity9645 , @entity221 , and @entity5406 was diagnosed with @entity195 ( @entity195 ). Her symptoms were refractory to conventional therapy. In 1999, @entity3043 was noticed in this @entity1 for the first time, and in 2000, her white blood cell count decreased to 0.94x10(9)/l with 1% myeloblasts and 24% neutrophils. Bone marrow examination showed mild hypocellularity with 8% myeloblasts and 6% mature neutrophils with @entity154 . A diagnosis of @entity2590 ( @entity2590 )-refractory @entity417 with @entity7139 was made. Despite marked @entity1398 , the @entity195 symptoms continued. Since her @entity1398 worsened to 0.24x10(9)/l with 21% neutrophils, the @entity1 underwent @entity1503 ( @entity1503 ) from an unrelated donor in July 2001. Myeloid engraftment was documented on day 26. Grade I @entity2132 occurred, but resolved spontaneously. Cyclosporin treatment was reduced gradually and discontinued 6 months after @entity1503 . Twenty-three months after @entity1503 , the @entity1 is doing well and has no signs or symptoms of @entity195 or @entity2590 . These observations suggest that allogeneic hematopoietic stem cell transplantation, which encompasses @entity1503 , may be an effective therapy in @entity1 with high-risk aggressive @entity195 .
